Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Mark Cagle

Physician Assistant, Medical Surprise, AZ Physician Assistant

NPI 1255950127 CMS profile 11165255

13921 W Grand Ave Ste 502, Surprise, AZ 85374

Open in the dashboard

General payments

$3,400

176 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Mark Cagle of Surprise, AZ is reported in the CMS Open Payments database as having received $3,400 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $837 36
2023 General $1,049 59
2022 General $897 50
2021 General $617 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Cagle
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mark Cagle were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mark Cagle Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $617 $156 $41–$563 $132
2022 $897 $185 $55–$649 $149
2023 $1,049 $199 $58–$717 $160
2024 $837 $206 $62–$740 $164
2025 $0 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AstraZeneca Pharmaceuticals LP $424 20 payments
  2. Novo Nordisk Inc $354 22 payments
  3. AbbVie, Inc. $340 19 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $306 14 payments
  5. GlaxoSmithKline, LLC. $251 14 payments
  6. Pfizer Inc. $228 11 payments
  7. Lilly USA, LLC $198 13 payments
  8. Gilead Sciences, Inc. $155 6 payments
  9. Amgen Inc. $100 6 payments
  10. Lundbeck LLC $87 4 payments
  11. Other $957 47 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $3,400 176 payments
Products named General payments · program years 2021–2024
  1. JARDIANCE Diabetes $267 12 payments
  2. TRELEGY ELLIPTA $251 14 payments
  3. FARXIGA $249 7 payments
  4. RYBELSUS $244 14 payments
  5. AIRSUPRA $212 5 payments
  6. Ozempic $206 13 payments
  7. BREZTRI $180 3 payments
  8. UBRELVY $142 9 payments
  9. PREVNAR 20 $126 6 payments
  10. JARDIANCE Diabetes $94 6 payments
  11. Other $2,177 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

1,805

Median for Physician Assistant: 241

Drug cost

$45,346

Median for Physician Assistant: $4,110

Branded share of claims

16.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 16 $16,068
Eliquis Apixaban Brand 13 $10,900
Paxlovid Nirmatrelvir/Ritonavir Brand 34 $1,352
Albuterol Sulfate Hfa Albuterol Sulfate Brand 45 $1,106
Methylprednisolone Generic 169 $1,091
Duloxetine Hcl Generic 22 $957
Atorvastatin Calcium Generic 77 $896
Levothyroxine Sodium Generic 68 $823
Gabapentin Generic 48 $765
Losartan Potassium Generic 55 $665

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$23,321

Of which drugs: $1,092

Medicare patients

189

Average age 77

Services billed

388

120 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Chronic kidney disease 33%
Ischemic heart disease 31%
Diabetes 29%
Depression 26%
Atrial fibrillation 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,064

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $119
$119 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $109
$109 — —
Leqembi
  • Eisai Inc. $68
$68 — —
REXULTI
  • Lundbeck LLC $66
$66 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record